Author: Scott Welch
Stripped out of the final bill is a provision to prevent the 2.8% Medicare pay cut to physicians.
Even though there are still challenges facing the industry, healthcare executives are optimistic heading into 2025, with a new Deloitte survey showing 60% of C-suite leaders have a favorable view of the coming year, up from 52% a year ago. Most, 69%, expect greater revenues, while 71% anticipate improved profitability. After years of navigating their businesses through ...
Private employers' expenditures are growing more than 70% faster than the national total, according to new government data.
Employers are bracing for healthcare costs to spike yet again in 2025, and that’s likely to push firms to pursue significant changes, experts said. The Business Group on Health’s annual look at trends to watch notes that healthcare costs are set to increase next year by the largest margin in a decade. And a survey released in ...
Ann Lewandowski knows all about pharmacy benefit managers, or PBMs, the companies that shape the U.S. drug market. Her job, as a policy advocate at drugmaker Johnson & Johnson, was to tell patient and physician groups about the PBMs’ role in high drug prices. Armed with that knowledge, Lewandowski filed a potentially groundbreaking lawsuit in ...
On the face of it, it may seem like the buzz around health equity is dying down. Less than a quarter of payer and health system executives cited health equity as a priority for 2025, a recent Deloitte survey found. But the facts haven’t changed. The U.S. healthcare system continues to have an abysmal record on most equity, access ...
The Centers for Medicare and Medicaid Services announced Friday that 64 Part B drugs will have a reduced price for Medicare patients at the pharmacy counter in the first quarter of 2025. CMS said patients may save between $1 and $10,818 per day on co-insurance costs for the Part B drugs included on the list. ...
Several major pharmaceutical companies, including Pfizer, Bristol Myers Squibb and Sanofi, are set to raise prices on more than 250 branded medications in the U.S. starting Jan. 1, 2025, according to a Reuter’s exclusive report. Data analyzed by healthcare research firm 3 Axis Advisors showed the price increases will affect a range of drugs, including Pfizer’s COVID-19 ...
As 2024 winds down, I continue to hear about companies rethinking employee health and wellness programs and what makes the biggest impact for their employees. To keep employees healthy, happy, and productive, companies are realizing they need to go well beyond the basics. Today’s corporate fitness programs are more innovative, inclusive, and focused on overall ...
The three giants charge less than the guppies but report higher, more consistent profits, according to a new Health Affairs study.